Targeting adenosine to improve cancer treatment
Enzyme-Mediated Depletion of Extracellular Adenosine and 5'methylthioadenosine as a Novel Anti-Cancer Therapeutic
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF TEXAS AT AUSTIN · NIH-10997743
This study is looking at how lowering certain molecules in the body can help make cancer treatments work better by boosting the immune system, which could lead to more effective ways to fight cancer for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS AT AUSTIN (nih funded) |
| Locations | 1 site (AUSTIN, UNITED STATES) |
| Trial ID | NIH-10997743 on ClinicalTrials.gov |
What this research studies
This research investigates how depleting adenosine and 5'methylthioadenosine can enhance anti-cancer therapies. By understanding the role of these molecules in suppressing immune responses within tumors, the study aims to develop new treatments that can boost the body's ability to fight cancer. The approach involves manipulating the enzymes that produce and degrade these substances, potentially leading to improved immune function and reduced tumor growth. Patients may benefit from therapies that are more effective in activating their immune systems against cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancers that exhibit high levels of adenosine in the tumor microenvironment.
Not a fit: Patients with cancers that do not significantly involve adenosine pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that enhance the immune response against tumors.
How similar studies have performed: Previous research has shown promising results in targeting adenosine pathways for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
AUSTIN, UNITED STATES
- UNIVERSITY OF TEXAS AT AUSTIN — AUSTIN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AL-KHALEDY, RANYA NOURA — UNIVERSITY OF TEXAS AT AUSTIN
- Study coordinator: AL-KHALEDY, RANYA NOURA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.